(Q30654054)

26 June 2017

1 reference

title

Optic neuritis and multiple sclerosis (English)

1 reference

26 June 2017

0 references

1 reference

1 reference

Söderström M

1

1 reference

26 June 2017

language of work or name

1 reference

1 June 2001

1 reference

26 June 2017

1 reference

26 June 2017

volume

79

1 reference

26 June 2017

issue

3

1 reference

26 June 2017

page(s)

223-227

1 reference

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Multiple sclerosis: an autoimmune disease of multifactorial etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Acute optic neuritis: a prospective study of risk factors for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Treatment recommendations for interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Optic neuritis: A population-based study in Olrnsted County, Minnesota

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

Multiple sclerosis is associated with genes within or close to the HLA-DR-DQ subregion on a normal DR15,DQ6,Dw2 haplotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

A long-term prospective study of optic neuritis: evaluation of risk factors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

What to tell the patient with optic neuritis about multiple sclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

Spinal cord atrophy and disability in MS: A longitudinal study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2001.790302.X

1 reference

7 January 2021

10.1034/J.1600-0420.2001.790302.X

Identifiers

DOI

1 reference

26 June 2017

1 reference